The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2019

Filed:

Jun. 16, 2015
Applicants:

Universite Paul Sabatier (Toulouse Iii), Toulouse, FR;

Centre National DE LA Recherche Scientifique, Paris, FR;

Centre Hospitalier Universitaire DE Toulouse, Toulouse, FR;

Institute National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;

Inventors:

Catherine Muller, Toulouse, FR;

Victor Laurent, Saint Sulpice, FR;

Adrien Guerard, Toulouse, FR;

Philippe Valet, Toulouse, FR;

Bernard Malavaud, Toulouse, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 31/453 (2006.01); A61K 31/713 (2006.01); C07K 14/715 (2006.01); C12N 15/113 (2010.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57434 (2013.01); A61K 31/453 (2013.01); A61K 31/713 (2013.01); C07K 14/7158 (2013.01); C07K 16/24 (2013.01); C07K 16/2866 (2013.01); C12N 15/1138 (2013.01); G01N 33/57492 (2013.01); G01N 33/6863 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C12N 2310/14 (2013.01); G01N 2333/7158 (2013.01); G01N 2800/56 (2013.01);
Abstract

The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumor in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumor cells obtained from said subject.


Find Patent Forward Citations

Loading…